

CORPORATE PROFILE

Knight Therapeutics Inc. (TSX: GUD), founded in 2014 by Jonathan Ross Goodman (co-founder of Paladin Labs Inc.), is a pan-American (ex-USA) specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight's Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight is headquartered in Montreal, Quebec, Canada and has over 700 employees.

OUR FOOTPRINT



Over \$336M in Revenue



11 Countries + distributors
in Central America and Caribbean



~ 700 Employees



+100 Products



+20 Partners



3 Manufacturing Plants
1 R&D Center
1 Regional Distribution Center

MARKET FACTS

(As at October 31, 2023)

Symbol: TSX: GUD
Share Price: \$4.55
Shares Outstanding: 104.4 M
Market Capitalization: \$474.8 M

MANAGEMENT TEAM

Samira Sakhia

President and CEO

Amal Khouri

Chief Business Officer

Arvind Utchanah

Chief Financial Officer

Susan Emblem

Global VP Human Resources

Monica Percario

Global VP Scientific Affairs

Leopoldo Bosano

VP, Manufacturing and Operations

Henrique Dias

Global Director of Marketing

FINANCIAL RESULTS

In '000s of CAD except per share amounts

	Q3 2023	Q4 2022	TTM Q3-23	TTM Q3-22
Revenues	81,500	81,655	335,657	270,181
Cash inflow (outflow) from operations	15,166	4,752	22,143	40,410
Adjusted EBITDA ²	15,512	13,821	61,839	45,907
Per share	0.15	0.12	0.59	0.40
	09-30-2023	12-31-2022		
Net cash ¹ , marketable securities and financial assets	236,921	279,165		
Per share	2.26	2.49		
Net asset value	814,665	825,857		
Per share	7.76	7.36		

¹ Net of bank loans

² Adjusted EBITDA is operating income (loss) adjusted to exclude amortization and impairment of intangible assets, depreciation, purchase price allocation accounting adjustments, impact of IAS 29 (accounting under hyperinflation), acquisition cost and non-recurring expenses but to include costs related to leases.

BOARD OF DIRECTORS

Jonathan Ross Goodman
(Executive Chairman)

James Gale (Lead Director)

Samira Sakhia

Robert Lande

Janice Murray

Michael Tremblay

Nicolás Sujoy

INVESTOR CONTACT

Knight Therapeutics Inc.

Samira Sakhia, President
and CEO

Tel: 514.484.4483


Arvind Utchanah, CFO

Tel: 598.2626.2344


E-mail: IR@knighttx.com

Website: www.knighttx.com


PRODUCT PORTFOLIO



REVENUE BY GEOGRAPHY




HEADCOUNT BY GEOGRAPHY




FINANCIAL HIGHLIGHTS

Net Revenue by Therapeutic Area



Adjusted EBITDA and Cash Flow from Operations



Note: Revenues exclude impact of hyperinflation/ IAS29 Adjusted EBITDA is a non-GAAP measure and defined as operating income or loss adjusted to exclude amortization and depreciation, impairment of non-current assets, purchase price allocation accounting adjustments, the impact of IAS 29 (accounting under hyperinflation), acquisition costs and non-recurring expenses but to include costs related to leases. Adjusted EBITDA per share is a non-GAAP ratio and calculated as adjusted EBITDA over number of common shares outstanding at the end of the respective period.

CORPORATE RESPONSIBILITY

Knight focuses on acquiring, in-licensing and commercializing innovative products, as well as developing, manufacturing and marketing specialty pharmaceutical products in Latin America, Canada and select international markets.

Knight continues to work diligently to ensure patients have access to Knight's medications in its markets, as well as develop branded generic products for Latin America to ensure that Knight provides cost effective treatments.

INVESTMENT HIGHLIGHTS

- Strong regional infrastructure with a unique footprint in Canada and across 10 countries in Latin America
- Experienced and dynamic management team
- Proven ability to develop a rich pipeline of new products and to secure mutually beneficial transactions
- Proven track record of profitable growth
- Financial strength to execute our strategy

ANALYST COVERAGE

Bloom Burton & Co.

David Martin
dmartin@bloomburton.com

Stifel GMP

Justin Keywood
jkeywood@stifel.com

Paradigm Capital Inc

Scott McAuley
smcauley@paradigmcap.com

Canaccord Genuity

Tania Armstrong-Whitworth
tarmstrongwhitworth@cgf.com

Research Capital

Andre Uddin
auddin@researchcapital.com

RBC Capital Markets

Douglas Miehm
douglas.miehm@research.rbcm.com